Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients from Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment

Circulation

Volumn 108, Issue 22, 2003, Pages 2751-2756

  Ansell, Benjamin J ^a   Navab, Mohamad ^a   Hama, Susan ^a   Kamranpour, Naeimeh ^a   Fonarow, Gregg ^a   Hough, Greg ^a   Rahmani, Shirin ^a   Mottahedeh, Rachel ^a   Dave, Ravi ^a   Reddy, Srinivasa T ^a   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cholesterol; Inflammation; Lipoproteins; Statins

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; STATINE; TRIACYLGLYCEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTERY WALL; ARTICLE; CELL FREE SYSTEM; CHEMOTAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MALE; MONOCYTE CHEMOTACTIC ACTIVITY; PRIORITY JOURNAL; TISSUE CULTURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; C-REACTIVE PROTEIN; CHEMOTAXIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COCULTURE TECHNIQUES; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIPIDS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MONOCYTES; PREDICTIVE VALUE OF TESTS; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 10744224101     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000103624.14436.4B     Document Type: Article

References (23)

1. Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol. 1998;82:13Q-21Q.
2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615-1622.
3. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. Am J Med. 1977;62: 707-714.
4. Castelli WP, Garrison RJ, Wilson WF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA. 1986;256:2835-2838.
5. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation. 2002;105:2-4.
6. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest. 1995;96:2758-2767.
7. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
8. Navab M, Hama-Levy S, Van Lenten BJ, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005-2019.
9. Navab M, Hama SY, Hough GP, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res. 2001;8:1308-1317.
10. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
11. Subbanagounder G, Watson AD, Berliner JA. Bioactive products of phospholipid oxidation: isolation, identification, measurement and activities. Free Radic Biol Med. 2000:28:1751-1761.
12. Subbanagounder G, Wong JW, Lee H, et al. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis: formation of these oxidized phospholipids in response to interleukin-1Β. J Biol Chem. 2002;277: 7271-7281.
13. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002:105:290-292.
14. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
15. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al, Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 2002:106:1127-1132.
16. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab. 2001:86:2032-2042.
17. Piguet PF, Grau GE, Allet B, et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med. 1987:166:1280-1289.
18. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999:45:2136-2141.
19. Van Lenten BJ, Wagner AC, Nayak D, et al. High-density lipoprotein loses its anti-inflammator properties during acute influenza A infection. Circulation. 2001:103:2283-2288.
20. Sampietro T, Bigazzi F, Dal Pino B, et al. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition? Circulation, 2002;105:11-14.
21. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481-488.
22. Bowry VW, Stanley K, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A. 1992:89:10316-10320.
23. Shishehbor MH, Aviles BJ, Brennan M-L, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003:289:1675-1680.